Coverage
-
June 14, 2013
A Pennsylvania federal judge on Friday approved a $150 million settlement, including $50 million in attorneys' fees, ending a direct purchaser antitrust class action accusing GlaxoSmithKline of filing sham petitions with federal authorities to delay generic alternatives to Flonase nasal spray.
2 other articles on this case.
View all »